Tonix Pharmaceuticals Holding Corp
$ 11.07
-6.82%
05 Jun - close price
- Market Cap 176,465,000 USD
- Current Price $ 11.07
- High / Low $ 11.90 / 10.87
- Stock P/E N/A
- Book Value 19.17
- EPS -14.66
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.42 %
- ROE -0.72 %
- 52 Week High 69.97
- 52 Week Low 10.87
About
Tonix Pharmaceuticals Holding Corp. The company is headquartered in Chatham, New Jersey.
Analyst Target Price
$46.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-03-12 | 2025-11-10 | 2025-08-11 | 2025-05-12 | 2025-03-18 | 2024-11-12 | 2024-08-16 | 2024-04-01 | 2024-03-25 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -2.93 | -3.9818 | -3.59 | -3.86 | -2.642 | -9.767 | -0.2288 | -19.28 | -0.18 | -0.86 | -1.83 | -2.68 |
| Estimated EPS | -2.55 | -3.19 | -3.59 | -6.83 | -3.09 | -3.91 | -2.93 | -3.27 | -0.39 | -1.64 | -1.49 | -2.75 |
| Surprise | -0.38 | -0.7918 | 0 | 2.97 | 0.448 | -5.857 | 2.7012 | -16.01 | 0.21 | 0.78 | -0.34 | 0.07 |
| Surprise Percentage | -14.902% | -24.8213% | 0% | 43.4846% | 14.4984% | -149.7954% | 92.1911% | -489.6024% | 53.8462% | 47.561% | -22.8188% | 2.5455% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TNXP
2026-05-28 20:38:49
Tonix Pharmaceuticals presented real-world claims analysis from Symphony Health at the 2026 ASCP Annual Meeting, revealing a substantial and persistent health burden due to opioid use in fibromyalgia patients. The study highlights the prevalent use of opioids despite guidelines, emphasizing the need for education on non-opioid treatments like Tonix's recently launched TONMYA. TONMYA, an FDA-approved non-opioid analgesic, is the first new fibromyalgia drug in over 15 years and aims to address this critical gap in treatment practices.
2026-05-28 20:09:52
Tonix Pharmaceuticals presented data from a real-world claims analysis at the 2026 ASCP Annual Meeting, highlighting the substantial and persistent health burden associated with opioid use in U.S. adults with fibromyalgia. The study, analyzing three years of claims data, found that a significant percentage of fibromyalgia patients were prescribed opioids despite guidelines discouraging their use. This presentation emphasizes the need for educating healthcare providers about non-opioid, FDA-approved alternatives like Tonix's recently launched TONMYA®.
2026-05-28 20:09:52
Tonix Pharmaceuticals presented data at the 2026 ASCP Annual Meeting revealing that opioids are still widely prescribed to U.S. fibromyalgia patients despite guidelines discouraging their use. A retrospective analysis of 261,776 adults showed significant opioid use across various age groups and insurance types, highlighting a persistent health burden. Tonix emphasized its non-opioid treatment, TONMYA, commercially launched in November 2025, to address this unmet medical need.
2026-05-28 06:10:48
Tonix Pharmaceuticals announced the publication of Phase 1 clinical data for TNX-1500, an Fc-modified anti-CD40L monoclonal antibody, in the Journal of Clinical Immunology. The study showed TNX-1500 was well-tolerated and effective in preventing organ transplant rejection, with a Phase 2 investigator-initiated study for kidney allograft rejection expected in late 2026. This antibody is designed to improve safety and tolerability compared to earlier generations, potentially offering a new treatment for transplant rejection and autoimmune diseases.
2026-05-28 04:09:52
This article provides an analysis of TNXP's financial performance, focusing on its revenue breakdown, profitability margins, and a comparison with competitors. Tonix Pharmaceuticals Holding Corp maintains a gross margin of 77.06% but shows negative operating and net margins, highlighting challenges in converting operations into shareholder value. The company's financial health is also benchmarked against industry leaders NBP and ARCT.
2026-05-27 17:09:53
Tonix Pharmaceuticals announced the publication of Phase 1 clinical data for TNX-1500, an Fc-modified anti-CD40L monoclonal antibody, in the Journal of Clinical Immunology. The study showed TNX-1500 was well-tolerated and effectively blocked T cell-dependent antibody responses, supporting its potential as a first-in-class treatment for preventing organ transplant rejection and autoimmune diseases. A Phase 2 investigator-initiated study for kidney transplant patients at Massachusetts General Hospital is expected to begin in the second half of 2026.
